#Human Chorionic Gonadotropin (hCG) Market Size

[soumyafwr]

Human Chorionic Gonadotropin (hCG) Market Overview, Size, Share and Forecast 2031

[nidarsanafwr]

https://meetupss.com/read-blog/51160_global-human-chorionic-gonadotropin-hcg-market-overview-size-share-and-forecast.html

Global Human Chorionic Gonadotropin (hCG) Market Overview, Size, Share and Forecast 2031

[gauricmi]

Human Chorionic Gonadotropin (HCG) Market: Rising Demand and Future Growth Prospects

A) Market Overview:

The global Human Chorionic Gonadotropin (HCG) market is estimated to be valued at US$ 710.88 million in 2022 and is expected to exhibit a CAGR of 6.5% over the forecast period of 2022-2030. HCG is a hormone produced during pregnancy and is widely used in fertility treatments and weight loss therapies. The market is driven by the increasing prevalence of infertility, growing awareness about HCG therapies, and advancements in medical technology and drug delivery systems.

B) Market Key Trends:

One of the key trends in the HCG market is the rising demand for HCG in fertility treatments. Infertility is a growing concern globally, and HCG injections are commonly used in assisted reproductive technologies to induce ovulation in women and enhance the chances of pregnancy. The increasing number of infertility cases, along with the success rate of HCG therapies, is fueling the demand for HCG products in the market.

For instance, Merck & Co., Inc., one of the key players in the HCG market, offers Pregnyl, a highly effective HCG drug used for the treatment of infertility. Pregnyl has shown promising results in inducing ovulation and supporting pregnancy, contributing to the growth of the market.

C) Porter's Analysis:

- Threat of new entrants: The Human Chorionic Gonadotropin (HCG) Market Size poses a moderate threat to new entrants due to the presence of established players with strong brand identities and a wide product portfolio.

- Bargaining power of buyers: The buyers in the HCG market have a moderate bargaining power, as there are several alternatives available in the market. However, the unique benefits and effectiveness of HCG products provide a competitive advantage to the suppliers.

- Bargaining power of suppliers: The suppliers in the HCG market have a moderate bargaining power, as there are multiple suppliers available in the market. However, the quality and reliability of HCG products are crucial factors for buyers, giving suppliers a strong position.

- Threat of new substitutes: The threat of new substitutes in the HCG market is low, as HCG is a unique hormone with specific therapeutic benefits that cannot be easily replaced.

- Competitive rivalry: The competitive rivalry in the HCG market is high, with several key players competing for market share. These players focus on product innovation, partnerships, and strategic collaborations to gain a competitive edge.

D) Key Takeaways:

- The global HCG market is expected to witness high growth, exhibiting a CAGR of 6.5% over the forecast period, due to increasing infertility cases worldwide and the effectiveness of HCG therapies. - North America is expected to dominate the HCG market, owing to advanced healthcare infrastructure, high awareness about fertility treatments, and favorable insurance reimbursement policies. - Key players operating in the global HCG market include Merck & Co., Inc., Ferring B.V., Fresenius SE & Co.KGaA, Lupin, Sun Pharmaceutical Industries Ltd, and others. These players focus on research and development, product launches, and acquisitions to strengthen their market position.

In conclusion, the global Human Chorionic Gonadotropin (HCG) market is poised for significant growth in the coming years. The rising demand for fertility treatments and the effectiveness of HCG therapies are driving market growth. Moreover, strategic initiatives by key players and advancements in medical technology are expected to further propel the market's expansion.

[ramkumarss]

Male Infertility Treatment Market size was valued at USD 4.3 billion in 2022 and is poised to grow at a significant CAGR of 4.93% from 2023-2029. male infertility refers to the inability of male to cause pregnancy in a fertile woman. A variety of the problems ranging from hormonal disturbances to physical, psychological problems can cause male infertility. Hormonal problems include hyperprolactinemia, hypothyroidism, panhypopituitarism and others. Physical problems include varicocele, torsion, damaged sperm ducts and others. Furthermore, Erectile dysfunction, premature ejaculation and ejaculatory incompetence may lead to male infertility. Although many treatments are available for male infertility, in many cases treatment will not work. In many of the cases, male infertility is caused by testicular damage that leads to the inability of sperm production. In addition, low sperm production and poor sperm quality are also major causes of male infertility. Drugs, hormonal therapy, and assisted reproductive technology make up the global male infertility treatment market (ART). Clomiphene citrate and tamoxifen are two drugs used to treat male infertility. Human chorionic gonadotropin hormone (hCG) and recombinant follicle stimulating hormone (rFSH) are two types of hormone therapy (rFSH). Patients are given gonadotropin treatment to increase their testosterone levels. If these medicines do not work after 6 to 12 months of treatment, assisted reproductive technologies may be a possibility. In vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), and zygote intrafallopian transfer (ZIFT) are the several types of assisted reproductive technologies (ZIFT). Request Sample : https://www.precisionbusinessinsights.com/request-sample/?product_id=18404

[market-insight-2023]

Global Endocrine Testing Market to Witness Growth in Coming Years

The new assessment focuses on Endocrine Testing Market submitted by the The Brainy Insights organization and considers commercial and basic market designs with recorded and measured market data. Endocrine Testing is anticipated to grow at a stunning CAGR of 6%, thereby garnering a revenue of USD 17.84 billion in the 2022-2030 timeframe. This research aims to give global Endocrine Testing market strategic & knowledge insights to assist in making informed investment decisions, decision making, and recognizing potential growth possibilities. The study report gives complex dynamics about the various aspects of the Endocrine Testing market, which assists organizations operating in the market make strategic development decisions. Additionally, the driving factors that are positively impacting the demand for Endocrine Testing market and restricting factors that are hampering the growth of Endocrine Testing market are discussed in detail, coupled with their influences on the Endocrine Testing market. The research delivers insights on the COVID-19 outbreak considering the alteration in customer demand & behaviour, re-routing the supply chain, purchasing patterns, major interventions of governments, and the dynamics of current market forces. This record will comprise all the significant aspects of the Endocrine Testing market, such as pros & cons, competition, openings, technological developments, regional analysis, etc.

Get the inside scoop with Sample report @ https://www.thebrainyinsights.com/enquiry/sample-request/12529

Further, the report provides a visual description of how all the organizations stand relatively based on their global Endocrine Testing market hold, geographic presence, competencies, employee & financial strength, and years of operations. Additionally, the SWOT analysis describes strengths, weaknesses, opportunities/possibilities, and threats that assist in accumulating the entire document with high efficiency & dependence. The report is an in-depth analysis of a wealthy supply of main factors responsible for developing the global Endocrine Testing market. The top-down & bottom-up strategies have been used to validate and estimate the market size of Endocrine Testing industry to evaluate the extent of multiple other dependent submarkets in the overall market.

Moreover, the report customization is done per the requirements of the clients. The study provides an in-depth analysis of each parameter, allowing our users to identify the most likely and perhaps the best trend in the current landscape. The companies are analyzed for both external and internal factors. The internal factors consist of the R&D base, consumer base, labour force, supply chain, market share in specific regions, and availability of technologies. The external factors include laws concerning product approval, per capita income, economic fluctuations, the performance of the industry in specific regions, and various other socio-economic parameters. The global Endocrine Testing market record provides a comprehensive analysis of the growth among segments & provides precise calculations & forecasts for sales by application and type in terms of value & volume.

Check complete table of contents with list of table and figures @ https://www.thebrainyinsights.com/report/endocrine-testing-market-12529

Based on the following items' applicability: Hospitals, Physicians Offices, Health Care Centers, Commercial Laboratories

The market segment by product type: Follicle stimulating hormone(FSH), Human Chorionic Gonadotropin (hCG), Thyroid Stimulating Hormone(TSH), Dehydroepiandrosterone sulfate (DHEAS), Prolactin, Progesterone, Insulin, Cortisol, Testosterone, Estradiol(E2), Luteinizing Hormone (LH)

The geographical portions of the report are as follows: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy and Rest of Europe), Asia Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia and Rest of South America), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of the Middle East and Africa)

The study's goal is to identify the following crucial global market participants: Quest Diagnostics, Thermo Fisher Scientific, Siemens Healthcare, Ortho Clinical Diagnostics, bioMerieux, Agilent Technologies, Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc, BioRad Laboratories, AB Sciex, F-Hoffmann La Roche AG, , LabCorp

The study report gives penetrations from market positioning & marketing channels to likely growth approaches, providing in-depth analysis for new players or existing contestants worldwide Endocrine Testing industry. The report compromises many graphs and flowcharts that distinctly explain the attractiveness of each segment globally and in various regions. The research document has comprehensively used the figures & numbers with the help of graphical & pictorial representation, which represents extra clarity on the global Endocrine Testing market.

Have Any Query? Ask Our Expert @ https://www.thebrainyinsights.com/enquiry/request-customization/12529

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D

Head of Business Development

Phone: +1-315-215-1633

Email: sales@thebrainyinsights.com

Web: www.thebrainyinsights.com

[nerdierthany0u-blog]

Human Chorionic Gonadotropin (HCG) Market Is Likely To Grow At The Uppermost CAGR During The Forecast Period 2018-2026

Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young boys, due to pituitary gland disorders and other diseases, due to which the testicles of the young males does not drop down naturally into the scrotum.

The key players operating the global human chorionic gonadotropin market include Merck & Co., Inc., EMD Sereno, Inc., Fresenius Kabi, Bristol Myers Squibb Company, Ferring BV, and Kamia Biomedical Company. Acris Antibodies developed a human chorionic gonadotropin hormone by recombinant DNA technology that helps to prevent the disintegration of the corpus luteum of the ovary thereby, maintaining levels of progesterone production for healthy pregnancy in females.

Request for the Customization Of the Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/1011

The HCG is usually administered as an injection under the skin into a muscle. The HCG can also be administered at home under the advice of a gynecologist or a pharmacist. The HCG levels can be determined with the help of urine or blood test. Result of specific test helps in the determining accurate measurement of the levels. These tests are mostly used to identify and confirm pregnancy or as a screening test to determine birth defects.

This primarily owes to the rising number of infertility cases as well as hormonal dysfunction among young males and females as a result of changing lifestyle. According to Mayo Clinic, around 25% of women fertility problems in the U.S. are a result of ovulation issues that are mostly caused due to dysfunction of human chorionic gonadotropin (HCG) hormone. 

[davidwalker2504]

Endocrine Testing Market Size, Share, Growth And Forecast To 2024

Global Endocrine Testing Market is expected to reach USD 13.02 billion by 2024. The endocrine system is a combined system that contains numerous glands situated throughout the body. Together with the nervous system, the endocrine system regulates and controls several internal physical functions. Although the nervous system uses nerve impulses as a means of control, the endocrine system uses chemical messenger molecules called hormones. With the help of network of glands, hormones are produced, stored, and secreted.

Thymus, adrenal glands, testes, hypothalamus, pituitary gland, ovaries, pineal gland, islet cells in the pancreas, thyroid, and parathyroid are glands of endocrine system. The endocrine testing market is estimated to grow at a significant CAGR of 8.0% over the future period as the scope and its applications are rising enormously across the globe.

Download Free Sample Report @ https://www.millioninsights.com/industry-reports/endocrine-testing-market/request-sample

Endocrine testing industry is segmented based on test type, technology, end use, and region. Insulin, estradiol (E2), cortisol, Follicle Stimulating (FSH), prolactin, Human Chorionic Gonadotropin (hCG), Thyroid Stimulating Hormone (TSH), Luteinizing Hormone (LH), testosterone, Dehydroepiandrosterone sulfate (DHEAS), progesterone, and other test type could be explored in endocrine testing market in the forecast period.

Thyroid Stimulating Hormone (TSH) sector accounted for the largest market share of endocrine testing industry and is estimated to lead the overall market in the coming years. This may be because of rising awareness regarding cardiovascular disorders and thyroid hormones levels. Moreover, insulin test is estimated to grow at fastest pace in the coming years, as growing diabetic population.

Highly used enhanced technology includes clinical chemistry, tandem mass spectrometry, sensor technology, immunoassay, monoclonal & polyclonal antibody technologies, and others that could be explored in the future period. During foremost period, the tandem mass spectrometry is estimated to lead the overall market. This may be because of rising use in combination with liquid chromatography. However, sensor technology segment is estimated to grow at fastest pace in the years to come, as rising use of biosensors in glucose monitoring for diabetes.

The market may be categorized based on end users like ambulatory care centers, hospital, commercial laboratory, and others could be explored in the foremost period. The hospital sector accounted for the largest market share and is estimated to continue its dominance in the forecast period. However, the commercial laboratory sector is estimated to grow at fastest pace in the coming years, as presence of skilled workers and accessibility of enhanced infrastructure.

Globally, North America accounted for the largest market share of endocrine testing and is estimated to continue its dominance in the upcoming years. The reason behind the overall market growth could be presence of advanced tertiary, secondary, and primary care hospitals, government initiative, enhanced compensation network, satisfactory government funding policy, and rising health awareness. Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth.

Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR of 9.1% in the foremost period. The aspects that may be ascribed to the growth comprise rising R&D expenditure by private agencies and government to improve therapeutic and diagnostic areas in the region. The developing countries like India and China are the major consumers of endocrine testing industry in this region, as developing healthcare infrastructure and government compensation policies.

The key players of endocrine testing market are Quest Diagnostics, Abbott Laboratories, LabCorp., AB Sciex, Hoffmann-La Roche Ltd., Agilent Technologies, DiaSorin, Biomedical Technologies, Bio-Rad Laboratories, and bioMerieux SA. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Browse Full Research Report with TOC @ https://www.millioninsights.com/industry-reports/endocrine-testing-market

Market Segment:

Test Type Outlook (Revenue, USD Million, 2013 - 2024) • Estradiol • FSH • hCG • LH • DHEAS • Progesterone • Testosterone • TSH • Prolactin • Cortisol • Insulin • Others

Technology Outlook (Revenue, USD Million, 2013 - 2024) • Tandem Mass Spectrometry • Immunoassay • Monoclonal & Polyclonal antibody technologies • Sensor technology • Clinical chemistry • Others

End Use Outlook (Revenue, USD Million, 2013 - 2024) • Hospital • Commercial Laboratory • Ambulatory Care Centers • Others

Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • U.S. • Canada • Europe • UK • Germany • Asia Pacific • Japan • China • Latin America • Brazil • Mexico • MEA • South Africa

Continued…

Get in Touch At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person: Ryan Manuel Research Support Specialist, USA Email: ryan@millioninsights.com

Global Headquarters Million Insights Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States Phone: 1-408-610-2300 Email: sales@millioninsights.com Asia Pacific Million Insights Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India Phone: 91-20-65300184

[soumyafwr]

https://www.articlefloor.com/human-chorionic-gonadotropin-hcg-market-overview-size-share-and-forecast-2031/

Human Chorionic Gonadotropin (hCG) Market Overview, Size, Share and Forecast 2031

[nidarsanafwr]

Global Human Chorionic Gonadotropin (hCG) Market Overview, Size, Share and Forecast 2031

[micropenisunveiled-blog]

Do You Have a Micropenis?               

Micropenis is a term used to describe a penis that is 2.5 standard deviations smaller than the mean (average) for the age and race of your child. This translates to an adult male with less than 3.66 inches, depending on the average length study used in measurement. During fetal development, deviations may occur as a result of a genetic aberration or be triggered by hormonal abnormalities.

Statistically, micropenis occurs in 0.6 percent of the population, making it a rare condition. The term is most commonly used when all other structures of the genitals, including the scrotum, testicles, and perineum, are "normal."

 Causes  

A micropenis develops during gestation and will often the only physiological abnormality noted in the pregnancy.

One of the possible causes of this is the low production of human chorionic gonadotropin (hCG) during the early part of the pregnancy. This is a hormone that stimulates the developing testes to produce testosterone.

After 14 weeks, penile growth falls under the influence of another hormone, known as luteinizing hormone (LH), which also stimulates testosterone in the so-called Leydig cells of the testicles. If the production of either or both of these fetal hormones is impeded, the child's penis length may be affected.

Genetics may also play a role. While there is no single gene that causes a micropenis, the condition is commonly linked to such chromosomal disorders as androgen insensitivity syndrome (AIS), Klinefelter syndrome, Turner syndrome, and Down syndrome.

There is also evidence that estrogen-based fertility drugs like diethylstilbestrol (DES) may cause smaller-than-normal penis size if taken during early pregnancy. While environmental pollutants are a less common cause, some research suggests that exposure to chlorinated pesticides during pregnancy may cause micropenis and other genital abnormalities in male babies.

 Diagnosis  

In newborns, it is vital that a doctor takes a proper measurement of the baby's penis when diagnosing micropenis. As opposed to a flaccid penis length (FPL), in which the penis is laid parallel to a ruler, a stretched penis length (SPL) should be used as it more closely correlates to the erect penis length in boys and men.

For this, the doctor needs to hold a rigid ruler held firmly against the pubis at a right angle. The penis is then held at the sides with calipers just below the glans (head) and stretched to its maximum length without pain. Newer syringe-like tools that can be placed over the penis and suction the organ to its fully stretched length are also available.

Correctly identifying a micropenis in babies is crucial as it offers the opportunity for a potentially effective treatment. The doctor should also explore conditions commonly associated with a micropenis, including problems with the pituitary gland or hypothalamus.  It is imperative that parents seek treatment for their male child early on, as treatments later in life are ineffective.

Defining Micropenis

While an SPL of less than 1.9 centimeters is diagnostic of micropenis in full-term newborn, for older boys and men, a micropenis is characterized by penis length 2.5 standard deviations (SD) smaller than the mean average for the age.

As a guideline, the Harriet Lane Handbook from John Hopkins University defines micropenis as follows:

6 to 12 months: less than 2.3 centimeters (0.9 inches)

1 to 2 years: less than 2.6 centimeters (1.02 inches)

2 to 3 years: less than 2.9 centimeters (1.14 inches)

3 to 4 years: less than 3.3 centimeters (1.3 inches)

4 to 5 years: less than 3.5 centimeters (1.38 inches)

5 to 6 years: less than 3.8 centimeters (1.5 inches)

6 to 7 years: less than 3.9 centimeters (1.54 inches)

7 to 8 years: less than 3.7 centimeters (1.46 inches)

8 to 9 years: less than 3.8 centimeters (1.5 inches)

9 to 10 years: less than 3.8 centimeters (1.5 inches)

10 to 11 years: less than 3.7 centimeters (1.46 inches)

Adult: less than 9.3 centimeters (3.66 inches)

The variations in mean penis size from age 7 is due to the differences in development as boys approach puberty. By puberty, it becomes far more difficult to define micropenis by centimeters alone; algorithmic calculations are needed until puberty is complete.

Differentiations in Boys

While the clinical definition of a micropenis seems to offer a definitive roadmap for diagnosis, that's not always the case. This is especially true in boys over the age of 8.

In fact, most prepubescent boys brought in by their parents because of an underdeveloped penis rarely have a micropenis. In most cases, the boy is either experiencing delayed puberty, obesity (obscuring the penis length with excessive pubic fat), or he simply has a larger frame compared to an otherwise normal penis.

In cases like these, the term "inconspicuous penis" may be more appropriately applied. It may be secondary to congenital conditions such as penoscrotal webbing (in which the scrotum extends up the underside of the penis, creating an indistinct junction between the two) and megaprepuce (in which the foreskin cannot retract and balloons abnormally).

 Treatment  

The treatment of micropenis will vary between children and adults. Given that the genitals of babies and toddlers are still developing, testosterone treatment can support penis growth, often significantly. Surgical options, while limited, may be explored in boys and men whose penises have reached their maximum growth.Adult men seeking surgical intervention should discuss all options and review the potential consequences and side effects of surgery.

Testosterone Therapy

A micropenis can be treated in infants and children with three monthly intramuscular (IM) injections of testosterone. Research has shown that one or two courses of three testosterone shots (25 to 50 milligrams) given in four-week intervals could increase the child's penis size to the reference range for his age.

For a male baby with a micropenis, circumcision should be delayed until the testosterone therapy is completed. Generally speaking, the therapy is most effective in children under 3 but may benefit boys up to the age of 8.

Gender Reassignment

In the past, young children with a micropenis often underwent gender reassignment surgery, more in response to a general cultural discomfort with small penis size rather a real medical need. Today, that practice has largely subsided, with most experts questioning its wisdom given the potential benefit of testosterone therapy, the need for lifelong male-to-female hormone therapy in later life, and the lack of individual consent.

If pursued, gender reassignment would generally be considered at a later age when the boy has the ability to make an informed choice for himself and has undergone extensive psychological evaluation.

Penis Enlargement Surgery

Some men with a micropenis will opt to undergo penis enlargement surgery (phalloplasty) with varying degrees of success. One such operation, called a suspensory ligament release, involves the detachment of the ligament that supports the penis during an erection.

Doing so allows the penis to lie in an obtuse rather than acute angle, creating the perception of greater length. Potential risks include nerve damage, loss of penial sensation, erectile dysfunction, and the retraction of the penis if scar tissue develops at the incision site.

Other forms of phalloplasty, such as flap surgery (grafting skin from another of the body), are less commonly pursued because they carry a considerable risk of complications and may interfere with sexual function.

Other techniques, such as silicone implants (prostheses), synthetic dermal fillers, and subcutaneous fat injections, are more likely to increase the girth rather than the length of the penis. Even if length gains are achieved, it would only affect the flaccid length, not the erect length, which would remain the same.

There are also commercially marketed penis pumps and stretchers that have not demonstrated consistent results in delivering gains in penis length. If achieved, they tend to be modest at best. These devices are intended for males with erectile dysfunction—an entirely separate concern.

 Complications  

From a practical standpoint, micropenis may complicate urination by making it difficult to direct the stream. Many men will simply compensate for this by sitting on the toilet when urinating.

On a more significant note, penis sizes of less than two inches are associated with a lower likelihood of conception. Moreover, some men with a micropenis will have a low sperm count as the result of an underlying pituitary disorder. In such cases, assisted reproductive techniques are available to significantly improve one's chances of conceiving.

Emotional Development and Relationships

While there are treatments available that may enhance a boy's penis size, the reality is that some boys (and men) will have a smaller-than-normal penis. While some people assume that this will cause inherent psychological harm to a boy, those beliefs are more reflective of our cultural attitudes about penis size rather than the boy's individual experience.

In fact, long-term research has shown that men with micropenises are no different in how they view their masculine self-image compared to men of average or above-average penis size. In the current popular culture; however, men may be saturated with images and ideas about size expectations which may lead to self perceived inadequacy.  Moreover, the condition has not been shown to interfere with a man's libido, sexual function, sexual satisfaction, ability to achieve an erection, or the ability to forge mutually gratifying sexual relationships.

[mrfrblogresearch02]

Point of Care Diagnostics/Testing Market Size  Analysis, Research Study 2027

Point of Care Diagnostics Market -Overview:

According to MRFR analysis, the global Point of Care Diagnostics Market Size is expected to register a CAGR of~11.6% from 2021 to 2027and hold a value of ~USD 36,740.3 million by 2027.

The medical equipment utilized to get an immediate result in examining various diseases, diabetes, cancer, heart diseases, are defined as point of care (POC) diagnostics. These devices include glucose monitoring kits, infectious disease testing kits, pregnancy and fertility testing kits, and drug abuse testing kits, to name a few.

The tests can be employed in a variety of circumstances, with each requiring a different course of action depending on the outcome. The drug screening kit can be used for several different purposes. In general, the test is used to determine whether or not a person has consumed any narcotic substance. Sportsmen and women can take the test to ensure that no narcotic substances are present before competing. The advent of portable POC devices supporting government policies is supplementing the POC diagnostics/testing market, with an increasing number of chronic conditions such as diabetes around the globe and a relatively small number of healthcare facilities in developing nations. In addition, market participants are introducing digital and wireless POC solutions to improve diagnosis efficiency and accuracy.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/10642 Regional Analysis: The market for point-of-care diagnostics is dominated by North America (which includes the United States and Canada). With the rising incidence and prevalence of lifestyle diseases, North America is gaining traction. More awareness of self-testing and home care goods and a considerable adoption of novel technologies are projected to play a crucial role in driving the point-of-care diagnostics market in North America. Healthcare product providers are merging and acquiring current market participants to extend their product availability across the region. Lacuna Diagnostics (US), a company that provides digital cytology point of care and telehealth services, was bought by Heska Corporation (US).

Owing to the limited availability of healthcare workers, various manufacturing facilities, changing demographics, and increasing consumer healthcare expectations, the Asia-Pacific point of care diagnostics/testing market is expected to be the fastest-growing market sector. Furthermore, comforting government rules, significant funding by industry participants, and innovative technically advanced solutions are all elements boosting the point of care diagnostics/testing market.

Segmentation: The global point of care diagnostics/testing market is categorized into product, end user, mode of purchase, and platform. Based on the product category, the market has been segregated into glucose monitoring, pregnancy & fertility testing, infectious disease testing, drug abuse testing, coagulation monitoring, cardiometabolic monitoring, cancer/tumor marker testing, hematology testing, urinalysis testing, cholesterol, and others. The glucose monitoring segment is expected to hold a considerable share of the market in 2020. Increasing POC urine hCG (Human Chorionic Gonadotropin) tests to diagnose pregnancy is fueling the market growth. Companies such as Abbott (US) are offering total β-hCG for the early detection of pregnancy. In addition, rising POC testing for early tumor detection is strengthening the demand for POC diagnostic products.

Based on end user, the global point of care diagnostics/testing market has been classified as hospitals & clinics, diagnostics centers, homecare/self-testing, and others. Hospitals &clinics held the largest segment share in 2020, owing to easy maneuvering, sample processing, and quick delivery of results. A laboratory information system also manages and stores patient’s test data for further reference, which further drives the market growth. Additionally, the demand for homecare/self-testing is accelerating due to increasing health risks during the pandemic outbreak and rising connectivity between patients and health care providers.

Based on mode of purchase, the global point of care diagnostics/testing market has been classified as over-the-counter (OTC) testing products and prescription-based testing products. The OTC testing products aim to hold a larger market share in the mode of purchase category. OTC products are sold without the prescription for generic disease-diagnosed patients. Theycomply with certain parameters that include the highest standards for efficacy and safety, Good Manufacturing Practice (GMP) manufacturing, stability testing, and labeling under 21 CFR 201.66. According to the FDA, over 300,000 marketed OTC drug products are categorized into 80 therapeutic classes. The largevariety and availability of the products are driving the point of care diagnostics/testing market.

Based on the platform, the global point of care diagnostics/testing market has been classified as immunoassays, molecular diagnostics, dipstick, and others. Immunoassays is estimated to hold the largest segment share in 2020, owing to the increasing demand forthe products for testing particular antibodies or a specific antigen in blood or other body fluids. The immunoassays-based POC test is carried out in countries with low resources and facilities. Among the immunoassays, lateral flow immunoassays are highly used for quick diagnosis as they are sensitive to specific antigens and offer quick & accurate results.

Key Players:

Some of the key players in the global point of care diagnostics/testing market are Abbott Laboratories (US), Siemens Healthineers GmbH (Germany), Chembio Diagnostics, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), PTS Diagnostics (US), Nova Biomedical (US), Quidel Corporation (US), Sekisui Diagnostics (US), Trinity Biotech (Ireland), AccuBioTech Co., Ltd.(China), Instrumentation Laboratory Company (Werfen) (US), and EKF Diagnostics Holdings plc (UK) among others.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/point-of-care-diagnostics-testing-market-10642

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[mrunalnerkarblog]

The presence of human chorionic gonadotropin (HCG) is commonly detected in early pregnancy tests.

[hemantallied]

Allied Market Research published a report, titled, Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others): Global Opportunity Analysis and Industry Forecast, 2017-2025. The report offers detailed insights on the top investment pockets, market size & share, driving forces & opportunities, strategic developments, and competitive landscape. According to the report, the global human chorionic gonadotropin (hCG) market garnered $688 million in 2017 and is expected to reach $1,239 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025. Surge in adoption of hCG in pain management & weight loss and increase in incidence of infertility-related issues drive the growth of the market. However, warnings and cautions issued by the USFDA regarding the side-effects of hCG therapy would restrain the market growth. Conversely, the implementation of recombinant technology would create new pathways for the market players in future.

[healthcare-market]

Endocrine Testing Market Pegged for Robust Expansion by 2027

Transparency Market Research (TMR) () has published a new report titled, ‘Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global endocrine testing market was valued at US$ 5.5 Bn in 2018 and is projected to expand at a CAGR of 6.4% from 2019 to 2027.

Overview

· Endocrine system is made up of endocrine glands that secrete hormones directly into the blood stream. Tests are performed to monitor levels of endocrine hormones (such as follicle stimulating hormone (FSH), Luteinizing Hormone (LH), estradiol, insulin and others) from biological samples. These tests aid in detection of deviation in the hormone production i.e. they help detect either hypersecretion (excess secretion) or hyposecretion (less secretion) that results in certain endocrine disorders such as infertility, menopause, thyroid dysfunction and others.

· The Endocrine Testing market is currently booming one, owing to consistent rise in diabetic and obese population resulting in development of several health disorders thereby enhancing the growth and acceptance of endocrine test kits and methodologies. Moreover endocrine test kit manufacturers are focusing on the development of efficient diagnostic test kits of high accuracy which are the factors anticipated to drive the growth of market.

· North America dominates the global endocrine testing market in 2018 and the trend is anticipated to continue during the forecast period. The growth of market in the region is attributed to increasing obesity and changing lifestyle and less physical inactivity resulting in several endocrine disorders., Also, increasing incidences of diabetes worldwide followed by constant technological upgradation in testing further propel the growth and adoption of endocrine testing platforms.

· Asia Pacific is likely to be a highly lucrative market for the Endocrine Testing market and it is expected to expand at a high CAGR during the forecast period. Vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies are key factors likely to boost endocrine testing market in Asia Pacific.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1645

Rise in Prevalence of Endocrine and Metabolic Disorders to Drive Global Endocrine Testing Market

· Disorders such as hypothyroidism, hyperthyroidism, diabetes mellitus, polycystic ovary syndrome (PCOS) among others are the most common endocrine & metabolic disorders among the global population. Thus, surge in number of people of above-mentioned conditions is anticipated to drive the growth of market.

Thyroid Stimulating Hormone (TSH) Test Segment to Dominate Endocrine Testing Market

· In terms of type, the global endocrine testing market has been segmented into Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test and Others (Gastrin, Thymosin, Secretin, etc.). Demand for Thyroid Stimulating Hormone (TSH) Test is anticipated to rise during the forecast period, as Thyroid disease is the most common in the general population, with its prevalence increasing with age and laboratory measurement of serum TSH is an essential tool for diagnosing and managing various thyroid disorders,  This in turn would drive the growth of segment.

Request for Analysis of COVID19 Impact on Endocrine Testing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1645

Clinical Chemistry Technology segment to dominate the Endocrine Testing Market

· In terms of technology, the global endocrine testing market has been segmented into Tandem Mass Spectrometry, Immunoassay technologies, Monoclonal and Polyclonal Antibody Technologies, Sensor Technologies, Clinical Chemistry Technologies and Others. Demand for Tandem Mass Spectrometry is anticipated to rise majorly due to the growing use of tandem mass spectrometry in combination with chromatography technique to overcome the challenges connected with old traditional techniques used for endocrine testing. Sensor technology is expected to be the fastest growing technology during the forecast period due to the rise in use of biosensors for diagnosis at home.

Commercial Laboratories Segment to be the Fastest Growing in the Endocrine Testing Market

· In terms of End User, the global endocrine testing market has been segmented into Hospitals, Commercial Laboratories, Ambulatory Care Centers, Home Based tests and Physician Offices. The commercial laboratories is the anticipated to be the fastest growing segment due to the availability of technologically advanced products for the rapid test results contributing to the growth of the segment.

Buy now Endocrine Testing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1645&ltype=S

North America to Dominate Global Endocrine Testing Market

· In terms of region, the global Endocrine Testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global Endocrine Testing market in 2018, followed by Europe.

· North America accounted for major share of the global Endocrine Testing market in 2018. High disease prevalence, supportive healthcare and payer infrastructure, and hub for key industry players are the major drivers of the endocrine testing market in the region.

· The Endocrine Testing market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. Unmet medical needs, untapped nature of the market, increase in awareness about diseases such as PCOS, Thyroid disorders and improving health care infrastructure are the key factors for endocrine testing market growth in the region

Competitive Landscape

· The global endocrine testing market is fragmented in terms of number of players. Key players in the global Endocrine Testing market include Agilent Technologies, F-Hoffmann La Roche Ltd., AB SCIEX, and Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, DiaSorin S.p.A, Beckman Coulter Inc, Siemens Healthineers and bioMerieux

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/rapidly-changing-lifestyle-habits-and-the-booming-geriatric-population-will-bring-multiple-growth-opportunities-for-the-periodontal-therapeutics-market-tmr-301283247.html

https://www.prnewswire.com/news-releases/strides-in-diabetic-foot-ulcers-treatment-market-anchored-by-focus-on-multidisciplinary-care-novel-wound-care-strategies-to-show-the-way-tmr-301288662.html

https://www.prnewswire.com/news-releases/strides-by-medical-enzyme-technology-market-to-open-new-vistas-in-human-diseases-diagnosis-valuation-to-touch-us-6-8-bn-by-2030-tmr-301292517.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

[snehalaxel]

Point of Care Pregnancy and Fertility Testing Market 2021 Investment Opportunity Analysis and Industry Share Forecast 2027

"

Point of Care Pregnancy and Fertility Testing Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://axelreports.com/request-sample/34615

A 360 degree outline of the competitive scenario of the Global Point of Care Pregnancy and Fertility Testing Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers seven-year assessment of Global Point of Care Pregnancy and Fertility Testing

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers regional analysis of Global Point of Care Pregnancy and Fertility Testing Market along with business profiles of several stakeholders.

It offers massive data about trending factors that will influence the progress of the Global Point of Care Pregnancy and Fertility Testing

Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-point-of-care-pregnancy-and-fertility-testing-industry-production-sale/34615

By Market Players: Alere Ani Biotech Oy Beckman Coulter bioMerieux Church & Dwight EKF Insight Pharmaceuticals Meridian OPKO Health Polymed Therapeutics Polymedco Quidel Radiometer Roche Siemens Healthcare Trinity By Type Human chorionic Gonadotropin (hcg) urine test FSH urine test Human chorionic Gonadotropin (hcg) blood test Luteinizing hormone (LH) urine test By Application Hypermarkets & supermarkets Gynaecology & fertility clinics Pharmacy Online sales Drugstores

A detailed outline of the Global Point of Care Pregnancy and Fertility Testing Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Point of Care Pregnancy and Fertility Testing Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Point of Care Pregnancy and Fertility Testing Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Point of Care Pregnancy and Fertility Testing Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/34615

Table of Contents:

Global Point of Care Pregnancy and Fertility Testing Market Overview

Economic Impact on Industry

Market Competition by Manufacturers

Production, Revenue (Value) by Region

Production, Revenue (Value), Price Trend by Type

Market Analysis by Application

Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global Point of Care Pregnancy and Fertility Testing Market Forecast

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: sales@axelreports.com/ Web: https://axelreports.com/

"